This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted)
- Highly Potent Broad-Spectrum Antiviral Lectin
- Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.
- Microbicide that can prevent viral transmission
- Therapeutic against enveloped virus-mediated diseases